Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: An ultrasonography study
Open accessAbstract
Aims Glucagon-like peptide 1 receptor agonists (GLP-1 RA) induce weight loss and reduction in adipose tissue, but the effects of GLP-1 RA on the distribution of fat deposits have been poorly investigated.Methods In 25 patients with type 2 diabetes (16 females and 9 males, mean age 63.5 ± 8.8 years), treated with GLP-1 RA (exenatide, n. 12; liraglutide, n.13), both before and 3 months after starting treatment, an abdominal ultrasonographic scan, with Doppler of renal arteries, and echocardiography were performed. Subcutaneous fat width (peri-umbilical and sub-xiphoid), deep fat deposits (pre-aortic, peri-renal, and epicardial), and renal resistive index (RI) were evaluated.Results GLP-1 RA induced highly significant (p < 0.001) decrease in BMI and in fat thickness at all the assessed sites, without differences between exenatide and liraglutide treatment. A slight decrease in RI (p = 0.055) was also found. The percent changes of fat thickness was different between sites (p < 0.025), and the changes in subcutaneous deposits showed no significant correlation (p = 0.064) with those of deep fat deposits.Conclusions A short course of treatment with GLP-1 RA, besides weight loss, induces a redistribution of adipose tissue deposits, possibly contributing to a better cardiovascular risk profile in patients with type 2 diabetes mellitus.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
12-week treatment with exenatide or liraglutide produces a mild yet significant reduction of EAT thickness, BMI, HbA1c and weight in T2DM patients, without difference between the two GLP-1RAs.
“Previously, one study reported that a 12-week short term treatment either with exenatide or liraglutide, determined a mild yet significant reduction of EAT thickness, BMI, HbA1c and weight in a smaller group of T2DM patients without difference between the two GLP-1RAs [126].”
From Dysregulated epicardial adipose tissue as a risk factor and potential therapeutic target of heart failure with preserved ejection fraction in diabetes (2022) · cites this paper as [126]
Exenatide treatment for 12 weeks was associated with a milder reduction of EAT thickness.
“A milder reduction of EAT thickness was also reported after 12 weeks of treatment with exenatide, a once weekly GLP-1 receptor agonist [17].”
From Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity (2020) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603 · see citing works
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583 · see citing works
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · see citing works
The Emerging Risk Factors Collaboration (2011) · The Lancet · doi:10.1016/s0140-6736(11)60105-0 · Cited by 1,216 · see citing works
Adipose tissue browning and metabolic health
Bartelt, A., & Heeren, J. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.204 · Cited by 1,177 · see citing works
Epicardial adipose tissue: Anatomic, biomolecular and clinical relationships with the heart
Iacobellis, G., Corradi, D., & Sharma, A. M. (2005) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0319 · Cited by 1,015 · see citing works
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · see citing works
Iacobellis, G., Ribaudo, M. C., Assael, F., Vecci, E., Tiberti, C., Zappaterreno, A., Di Mario, U., & Leonetti, F. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030698 · Cited by 842 · see citing works
Williamson, D. F., Pamuk, E. R., Thun, M. J., Flanders, D. W., Byers, T., & Heath, C. W. (1995) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117386 · Cited by 524 · see citing works
Liu, J., Fox, C. S., Hickson, D. A., May, W. D., Hairston, K. G., Carr, J. J., & Taylor, H. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1378 · Cited by 521 · see citing works
Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J. P., Verhoeven, R., Bugáňová, I., & Madsbad, S. (2007) · Diabetes Care · doi:10.2337/dc06-2593 · Cited by 467 · see citing works
Kim, D. S., MacConell, L., Zhuang, D., Kothare, P. A., TRAUTMANN, M. E., Fineman, M. S., & Taylor, K. (2007) · Diabetes Care · doi:10.2337/dc06-2375 · Cited by 447 · see citing works
Suzuki, R., Watanabe, S., Hirai, Y., Akiyama, K., NISHIDE, T., MATSUSHIMA, Y., Murayama, H., OHSHIMA, H., Shinomiya, M., Shirai, K., et al. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90284-v · Cited by 318 · see citing works
Jendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312 · see citing works
Chaston, T. B., & Dixon, J. B. (2008) · International Journal of Obesity · doi:10.1038/sj.ijo.0803761 · Cited by 300 · see citing works
The future of obesity reduction: beyond weight loss
Ross, R., & Bradshaw, A. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.78 · Cited by 258 · see citing works
Substantial changes in epicardial fat thickness after weight loss in severely obese subjects
Iacobellis, G., Singh, N., Wharton, S., & Sharma, A. M. (2008) · Obesity · doi:10.1038/oby.2008.251 · Cited by 238 · see citing works
Aerobic exercise training reduces epicardial fat in obese men
Kim, M.-K., Tomita, T., Kim, M.-J., Sasai, H., Maeda, S., & Tanaka, K. (2008) · Journal of Applied Physiology · doi:10.1152/japplphysiol.90756.2008 · Cited by 184 · see citing works
Jensterle Sever, M., Kocjan, T., Pfeifer, M., Kravos, N. A., & Janez, A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0797 · Cited by 175 · see citing works
Sabir, N., Sermez, Y., Kazil, S., et al. (2001) · European Journal of Ultrasound · doi:10.1016/s0929-8266(01)00153-7 · Cited by 111 · see citing works
Liu, K. H., Chan, Y. L., Chan, W. B., Chan, J. C. N., & Chu, C. W. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1578 · Cited by 110 · see citing works
Excess Visceral Adipose Tissue/Ectopic Fat
Després, J. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.063 · Cited by 101 · see citing works
Obesity in the elderly: More complicated than you think
Cetin, D. C., & Nasr, G. (2014) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81a.12165 · Cited by 94 · see citing works
Clinical application of transthoracic ultrasonography in inpatients with pneumonia
Sperandeo, M., Carnevale, V., Muscarella, S., SPERANDEO, G., Varriale, A., Filabozzi, P., Piattelli, M. L., D’Alessandro, V., Copetti, M., Pellegrini, F., et al. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02367.x · Cited by 85 · see citing works
Self-citationGLP ‐1 Receptor Agonists: Effects on Cardiovascular Risk Reduction
Lorber, D. (2013) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12000 · Cited by 77 · see citing works
Kawai, T., Kamide, K., Onishi, M., Yamamoto‐Hanasaki, H., Baba, Y., Hongyo, K., Shimaoka, I., Tatara, Y., Takeya, Y., Ohishi, M., et al. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr054 · Cited by 72 · see citing works
Sonographic evaluation of visceral fat by measuring para‐ and perirenal fat
Kawasaki, S., Aoki, K., Hasegawa, O., Numata, K., Tanaka, K., Shibata, N., Shimada, S., Okamura, A., & Terauchi, Y. (2007) · Journal of Clinical Ultrasound · doi:10.1002/jcu.20426 · Cited by 69 · see citing works
Bazzocchi, A., Diano, D., Ponti, F., Salizzoni, E., Albisinni, U., Marchesini, G., & Battista, G. (2013) · Nutrition · doi:10.1016/j.nut.2013.11.013 · Cited by 54 · see citing works
Is there a place for incretin therapies in obesity and prediabetes?
Holst, J. J., & Deacon, C. F. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.01.004 · Cited by 44 · see citing works
The Role of Ultrasonography in the Evaluation of Abdominal Fat
Bazzocchi, A., Filonzi, G., Ponti, F., et al. (2013) · Academic Radiology · doi:10.1016/j.acra.2013.07.009 · Cited by 31 · see citing works
Christensen, D. L., Faurholt‐Jepsen, D., Færch, K., et al. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0474-x · Cited by 15 · see citing works
Bacchi, E., Negri, C., Tarperi, C., Baraldo, A., Faccioli, N., Milanese, C., Zanolin, M. E., Lanza, M., Cevese, A., Bonora, E., et al. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0519-1 · Cited by 14 · see citing works
Therapy for Obesity Based on Gastrointestinal Hormones
Bagger, J. I., Christensen, M., Knop, F. K., & Vilsbøll, T. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.339 · Cited by 10 · see citing works
Sperandeo, M., Varriale, A., D’Amico, G., et al. (2007) · European Journal of Inflammation · doi:10.1177/1721727x0700500207 · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131 · see citing works
Epicardial adipose tissue in contemporary cardiology
Iacobellis, G. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00679-9 · Cited by 797 · see citing works
Dutour, A., Abdesselam, I., Ancel, P., Kober, F., Mrad, G., Darmon, P., Ronsin, O., Pradel, V., Lesavre, N., Martin, J. C., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12680 · Cited by 262 · see citing works
Liraglutide causes large and rapid epicardial fat reduction
Iacobellis, G., Mohseni, M., Bianco, S. D., & Banga, P. K. (2017) · Obesity · doi:10.1002/oby.21718 · Cited by 251 · see citing works
González, N., Moreno-Villegas, Z., González-Bris, A., Egido, J., & Lorenzo, Ó. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0528-4 · Cited by 211 · see citing works
“Another GLP-1R agonist (exenatide), reduced EAT and subcutaneous and liver fat in T2DM patients, in a similar fashion than liraglutide [110].”
BackgroundIacobellis, G., & Villasante Fricke, A. C. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz042 · Cited by 168 · see citing works
Clinical importance of epicardial adipose tissue
Nagy, E., Jermendy, A. L., Merkely, B., & Maurovich-Horvat, P. (2017) · Archives of Medical Science · doi:10.5114/aoms.2016.63259 · Cited by 121 · see citing works
Human epicardial fat expresses glucagon-like peptide 1 and 2 receptors genes
Iacobellis, G., Camarena, V., Sant, D., & Wang, G. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-109563 · Cited by 112 · see citing works
Epicardial fat: a new cardiovascular therapeutic target
Iacobellis, G. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.01.004 · Cited by 104 · see citing works
Malavazos, A. E., Iacobellis, G., Dozio, E., Basilico, S., Di Vincenzo, A., Dubini, C., Menicanti, L., Vianello, E., Meregalli, C., Ruocco, C., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad050 · Cited by 100 · see citing works
Myasoedova, V. A., Parisi, V., Moschetta, D., Valerio, V., Conte, M., Massaiu, I., Bozzi, M., Celeste, F., Leosco, D., Iaccarino, G., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01738-2 · Cited by 93 · see citing works
Lima-Martínez, M. M., Paoli, M., Rodney, M., Balladares, N., Contreras, M., D’Marco, L., & Iacobellis, G. (2016) · Endocrine · doi:10.1007/s12020-015-0710-y · Cited by 92 · see citing works
van Eyk, H. J., Paiman, E. H. M., Bizino, M. B., de Heer, P., Geelhoed-Duijvestijn, P. H., Kharagjitsingh, A. V., Smit, J. W. A., Lamb, H. J., Rensen, P. C. N., & Jazet, I. M. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0890-5 · Cited by 90 · see citing works
GLP-1 agonists for weight loss: pharmacology and clinical implications.
Moore, P. W., Malone, K., VanValkenburg, D., Rando, L. L., Williams, B. C., Matejowsky, H. G., Ahmadzadeh, S., Shekoohi, S., Cornett, E. M., & Kaye, A. D. (2023) · Advances in Therapy · doi:10.1007/s12325-022-02394-w · Cited by 86 · see citing works
Hammoud, S. H., AlZaim, I., Al-Dhaheri, Y., Eid, A. H., & El-Yazbi, A. F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.707126 · Cited by 87 · see citing works
Epicardial adipose tissue feeding and overfeeding the heart
Iacobellis, G., & Barbaro, G. (2019) · Nutrition · doi:10.1016/j.nut.2018.07.002 · Cited by 82 · see citing works
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Rinaldi, L., Coviello, F., Di Martino, A., Albanese, G., Colantuoni, S., Medicamento, G., et al. (2022) · Biomolecules · doi:10.3390/biom12020176 · Cited by 62 · see citing works
Effect of glucagon-like peptide-1 (GLP-1) analogues on epicardial adipose tissue: A meta-analysis
Berg, G., Barchuk, M., Lobo, M., & Nogueira, J. P. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102562 · Cited by 36 · see citing works
- Authors
- Morano, S., Romagnoli, E., Filardi, T., Nieddu, L., Mandosi, E., Fallarino, M., Turinese, I., Dagostino, M. P., Lenzi, A., & Carnevale, V.
- Affiliations
- Policlinico Umberto I (IT)
- Casa Sollievo della Sofferenza (IT)
- Corresponding author
- Morano, Susanna
- ORCID
- Venue
- Acta Diabetologica
- Published
- 2015-01-11
- Volume
- 52
- Issue
- 4
- Pages
- 727-732
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- OpenAlex
- W2028157712
- Cited by
- 110
- References
- 34
- Citations by year
- 2026: 10 · 2025: 18 · 2024: 10 · 2023: 14 · 2022: 19 · 2021: 9 · 2020: 3 · 2019: 4 · 2018: 8 · 2017: 9 · 2016: 4 · 2015: 2
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Acta Diabetologica (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, body fat distribution, adipose tissue redistribution, exenatide, liraglutide, subcutaneous fat thickness, renal resistive index, renal artery Doppler, body mass index, weight loss, cardiovascular risk
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Adipose Tissue, Adult, Aged, Cardiovascular Diseases, Cardiovascular System, Diabetes Mellitus, Type 2, Echocardiography, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Middle Aged, Peptides, Risk Factors, Time Factors, Ultrasonography, Venoms, Body Fat Distribution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
